Treosulfan and gemcitabine in metastatic uveal melanoma patients:: results of a multicenter feasibility study
Treosulfan and gemcitabine in metastatic uveal melanoma patients:: results of a multicenter feasibility study
复制标题
DOI：
10.1097/01.car.0000070764.25457.ca
复制
发表时间：
2003-06-01
影响因子：
2.3
通讯作者：
Reinhold, U
中科院分区：
文献类型：
--
作者：
Pföhler, C;Cree, IA;Reinhold, U
目前尚无有效的治疗转移性葡萄膜黑色素瘤的方法。然而，最近一项基于atp的肿瘤化学敏感性试验结果显示，曲硫丹+吉西他滨在多达80%的肿瘤标本中具有一致的活性。在这项研究中，我们描述了在不同的欧洲中心观察到的转移性葡萄膜黑色素瘤患者使用该药物联合治疗的首次临床结果。临床病例系列转移性葡萄膜黑色素瘤患者在7个不同的中心接受曲硫丹+吉西他滨治疗。研究包括14名患者，其中13名未接受治疗，1名接受化疗免疫治疗。患者接受曲硫芬+吉西他滨四种不同剂量方案。评估反应率、无进展生存期和总生存期以及毒性。对14例患者的分析显示，1例完全缓解，3例部分缓解，8例病情稳定。客观缓解率为28.6%，中位总生存期为61周[95%可信区间（CI） 54-133周]，无进展生存期为28.5周（95% CI 13-62周），1年生存率为80%。这些药物耐受性良好。最常见的副作用是白细胞和血小板减少症。这些初步结果提示曲硫丹+吉西他滨治疗转移性葡萄膜黑色素瘤的潜在疗效，值得进一步的对照研究。(C) 2003利平科特·威廉姆斯·威尔金斯。
No effective treatment currently exists for metastatic uveal melanoma. However, recent results obtained by an ATP-based tumor chemosensitivity assay have shown consistent activity of treosulfan + gemcitabine in up to 80% of tumor specimens tested. In this study we describe the first clinical results observed with this drug combination at different European centers in patients with metastatic uveal melanoma. Clinical case series of patients with metastatic uveal melanoma were treated with treosulfan+gemcitabine at seven different centers. Fourteen patients, 13 previously untreated and one pretreated with chemoimmunotherapy, were included in the study. Patients received treosulfan+gemcitabine in four different dose regimens. The response rates, progression-free and overall survival, and toxicity were evaluated. The analysis of 14 patients revealed one complete response, three partial responses and a stable disease in eight cases. The objective response rate was 28.6%, the median overall survival was 61 weeks [95% confidence interval (CI) 54-133 weeks], the progression-free survival was 28.5 weeks (95% CI 13-62 weeks) and the 1-year survival rate was 80%. The drugs were well tolerated. The most common side-effects were leuko- and thrombocytopenia. These preliminary results suggest potential therapeutic benefit of treosulfan + gemcitabine treatment in metastatic uveal melanoma and warrant further controlled studies. (C) 2003 Lippincott Williams Wilkins.